Minor Use Minor Species Development of Drugs (R01)

Key facts

Copied from the official Grants.gov record. Last verified October 29, 2026.

Program name

Minor Use Minor Species Development of Drugs (R01)

Issuing agency

Food and Drug Administration (Department of Health and Human Services)

Opportunity number

PAR-24-216

Funding type

Grant

Funding purpose

Agriculture, Consumer Protection, Food and Nutrition

Status

Open (posted)

Application deadline

Closes January 29, 2027Agency note: Application Due Dates are as follows: July 29, 2024; January 31, 2025; July 25, 2025; January 30, 2026; July 24, 2026; January 29, 2027

Published award range

Up to $250,000

Estimated total program funding

$250,000

Cost sharing or match required

No

Eligible applicants (official categories)

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities/Indian housing authorities
• Native American tribal organizations (other than Federally recognized tribal governments)
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Private institutions of higher education
• For profit organizations other than small businesses
• Small businesses
• Others (see Additional Information on Eligibility)

Relevant to

Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.

Geographic restrictions

None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.

Assistance Listing (CFDA)

93.103

Official source

View on Grants.gov ↗ · Agency information link ↗

Application URL

www.grants.gov/search-results-detail/354573 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.

Source identifier

Grants.gov opportunity ID 354573 · Funding opportunity number PAR-24-216

Posted

May 29, 2024 · Source last updated May 29, 2024

Last verified

October 29, 2026 (against Grants.gov)

Data completeness

100% of key fields published by the source

Record confidence

highVerified against the official source; key fields present; no open issues.

Eligibility details (from the agency)

• Faith-based or Community-based Organizations• Regional Organizations• Non-domestic (non-U.S.) Entities (Foreign Organizations)

Description (from the official listing)

This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs. Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants. The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516. FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.

Agency contact

Terrin Brown Grantor
terrin.brown@fda.hhs.gov